



Université de Poitiers

Faculté de Médecine et Pharmacie

Année 2021

THESE

POUR LE DIPLOME D'ETAT
DE DOCTEUR EN MEDECINE
(décret du 16 janvier 2004)

Présentée et soutenue publiquement
le 24 septembre 2021 à Poitiers
par **Monsieur Dorian TRICARD**

Progression of myopia in children and teenagers: a nationwide longitudinal study

Composition du Jury

Président : Monsieur le Professeur Pierre INGRAND

Membres : Monsieur le Professeur Nicolas LEVEZIEL
Monsieur le Professeur Pierre INGRAND
Monsieur le Professeur Xavier DUFOUR
Madame le Docteur Roxane FLAUSSE

Directeur de thèse : Monsieur le Professeur Nicolas LEVEZIEL

LISTE DES ENSEIGNANTS DE MEDECINE

Professeurs des Universités-Praticiens Hospitaliers

- BOULETI Claire, cardiologie
- BOURMEYSTER Nicolas, biologie cellulaire
- BRIDOUX Frank, néphrologie
- BURUCOA Christophe, bactériologie-virologie
- CHEZE-LE REST Catherine, biophysique et médecine nucléaire
- CHRISTIAENS Luc, cardiologie
- CORBI Pierre, chirurgie thoracique et cardio-vasculaire
- COUDROY Rémi, médecine intensive-réanimation
- DAHYOT-FIZELIER Claire, anesthésiologie-réanimation et médecine péri-opératoire
- DEBAENE Bertrand, anesthésiologie-réanimation et médecine péri-opératoire
- DEBIAIS Françoise, rhumatologie
- DROUOT Xavier, physiologie
- DUFOUR Xavier, Oto-Rhino-Laryngologie
- FAURE Jean-Pierre, anatomie
- FRASCA Denis, anesthésiologie-réanimation
- FRITEL Xavier, gynécologie-obstétrique
- GERVAIS Elisabeth, rhumatologie
- GICQUEL Ludovic, pédiatrie
- GILBERT Brigitte, génétique
- GOMBERT Jean-Marc, immunologie
- GOUJON Jean-Michel, anatomie et cytologie pathologiques
- GUILLIVIN Rémy, radiologie et imagerie médicale
- HAUET Thierry, biochimie et biologie moléculaire
- INGRAND Pierre, biostatistiques, informatique médicale
- ISAMBERT Nicolas, cancérologie
- JAAFARI Nematollah, psychiatrie d'adultes
- JABER Mohamed, cytologie et histologie
- JAYLE Christophe, chirurgie thoracique et cardio-vasculaire
- KARAYAN-TAPON Lucie, cancérologie
- KEMOUN Gilles, médecine physique et de réadaptation (en disponibilité)
- KRAIMPS Jean-Louis, chirurgie viscérale et digestive (retraite au 01/01/2022)
- LECLERE Franck, chirurgie plastique, reconstructrice
- LECRON Jean-Claude, biochimie et biologie moléculaire
- LELEU Xavier, hématologie
- LEVARD Guillaume, chirurgie infantile (retraite au 01/11/2021)
- LEVEQUE Nicolas, bactériologie-virologie
- LEVEZIEL Nicolas, ophtalmologie
- MACCHI Laurent, hématologie
- MCHEIK Jiad, chirurgie infantile
- MEURICE Jean-Claude, pneumologie
- MIGEOT Virginie, santé publique
- MILLOT Frédéric, pédiatrie, oncologie pédiatrique
- MIMOZ Olivier, médecine d'urgence
- NEAU Jean-Philippe, neurologie
- ORIOT Denis, pédiatrie
- PACALIN Marc, gériatrie
- PERAULT-POCHAT Marie-Christine, pharmacologie clinique
- PERDRISOT Rémy, biophysique et médecine nucléaire
- PIERRE Fabrice, gynécologie et obstétrique
- PRIES Pierre, chirurgie orthopédique et traumatologique
- RAMMAERT-PALTRIE Blandine, maladies infectieuses

- RICHER Jean-Pierre, anatomie
- RIGAUD Philippe, neurochirurgie
- ROBERT René, médecine intensive-réanimation (retraite au 01/12/2021)
- ROBLAT France, maladies infectieuses, maladies tropicales
- ROBLAT Pascal, médecine interne
- SAULNIER Pierre-Jean, thérapeutique
- SCHNEIDER Fabrice, chirurgie vasculaire
- SILVAIN Christine, hépato-gastro-entérologie
- TASU Jean-Pierre, radiologie et imagerie médicale
- THIERRY Antoine, néphrologie
- THILLE Arnaud, médecine intensive-réanimation
- TOUGERON David, gastro-entérologie
- WAGER Michel, neurochirurgie
- XAVIER Jean, pédopsychiatrie

Maîtres de Conférences des Universités-Praticiens Hospitaliers

- ALBOUY-LLATY Marion, santé publique
- ALLAIN Géraldine, chirurgie thoracique et cardio-vasculaire
- BEN-BRIK Eric, médecine du travail (en détachement)
- BILAN Frédéric, génétique
- BOISSON Matthieu, anesthésiologie-réanimation et médecine péri-opératoire (en mission 1 an jusqu'à fin octobre 2021)
- CAYSSIALS Emilie, hématologie
- CREMNITER Julie, bactériologie-virologie
- DIAZ Véronique, physiologie
- FROUIN Eric, anatomie et cytologie pathologiques
- GACHON Bertrand, gynécologie-obstétrique
- GARCIA Magali, bactériologie-virologie
- GUENEZAN Jérémy, médecine d'urgence
- JAVAGUE Vincent, néphrologie (en mission 1 an a/c du 12/07/2021)
- JUTANT Etienne-Marie, pneumologie
- KERFORNE Thomas, anesthésiologie-réanimation et médecine péri-opératoire
- LAFAY-CHEBASSIER Claire, pharmacologie clinique
- LIU Evelyne, gériatrie
- MARTIN Mickaël, médecine interne
- PALAZZO Paola, neurologie (en dispo 3 ans à/c du 01/07/2020)
- PERRAUD Estelle, parasitologie et mycologie
- PICHON Maxime, bactériologie-virologie
- SAPANET Michel, médecine légale
- THUILLIER Raphaël, biochimie et biologie moléculaire

Professeur des universités

- PELLERIN Luc, biochimie et biologie moléculaire

Professeur des universités de médecine générale

- BINDER Philippe

Professeur associé des universités des disciplines médicales

- FRAT Jean-Pierre, médecine intensive-réanimation

Maître de Conférences associé des universités des disciplines médicales

- HARIKA-GERMANEAU Ghina, psychiatrie d'adultes

Professeurs associés de médecine générale

- ARCHAMBAULT Pierrick
- BIRAULT François
- FRECHE Bernard
- MIGNOT Stéphanie
- PARTHENAY Pascal
- VALETTE Thierry
- VICTOR-CHAPLET Valérie

Maîtres de Conférences associés de médecine générale

- AUDIER Pascal
- BRABANT Yann
- JEDAT Vincent

Enseignant d'Anglais

- DEBAIL Didier, professeur certifié

Professeurs émérites

- GIL Roger, neurologie (08/2023)
- GUILHOT-GAUDEFROY François, hématologie et transfusion (08/2023)
- HERPIN Daniel, cardiologie (08/2023)
- MARECHAUD Richard, médecine interne (24/11/2023)
- RICCO Jean-Baptiste, chirurgie vasculaire (08/2022)
- SENON Jean-Louis, psychiatrie d'adultes (08/2023)
- TOUCHARD Guy, néphrologie (08/2023)

Professeurs et Maîtres de Conférences honoraires

- AGIUS Gérard, bactériologie-virologie
- ALCALAY Michel, rhumatologie
- ALLAL Joseph, thérapeutique (ex-émérite)
- ARIES Jacques, anesthésiologie-réanimation
- BABIN Michèle, anatomie et cytologie pathologiques
- BABIN Philippe, anatomie et cytologie pathologiques
- BARBIER Jacques, chirurgie générale (ex-émérite)
- BARRIERE Michel, biochimie et biologie moléculaire
- BECQ-GIRAUDON Bertrand, maladies infectieuses, maladies tropicales (ex-émérite)
- BEGON François, biophysique, médecine nucléaire
- BOINOT Catherine, hématologie – transfusion
- BONToux Daniel, rhumatologie (ex-émérite)
- BURIN Pierre, histologie
- CARRETIER Michel, chirurgie viscérale et digestive (ex-émérite)
- CASTEL Olivier, bactériologie-virologie ; hygiène
- CASTETS Monique, bactériologie -virologie – hygiène
- CAVELLIER Jean-François, biophysique et médecine nucléaire
- CHANSIGAUD Jean-Pierre, biologie du développement et de la reproduction
- CLARAC Jean-Pierre, chirurgie orthopédique
- DABAN Alain, oncologie radiothérapie (ex-émérite)
- DAGREGORIO Guy, chirurgie plastique et reconstructrice
- DESMAREST Marie-Cécile, hématologie
- DEMANGE Jean, cardiologie et maladies vasculaires

- DORE Bertrand, urologie (ex-émérite)
- EUGENE Michel, physiologie (ex-émérite)
- FAUCHERE Jean-Louis, bactériologie-virologie (ex-émérite)
- FONTANEL Jean-Pierre, Oto-Rhino Laryngologie (ex-émérite)
- GOMES DA CUNHA José, médecine générale (ex-émérite)
- GRIGNON Bernadette, bactériologie
- GUILLARD Olivier, biochimie et biologie moléculaire
- GUILLET Gérard, dermatologie
- JACQUEMIN Jean-Louis, parasitologie et mycologie médicale
- KAMINA Pierre, anatomie (ex-émérite)
- KITZIS Alain, biologie cellulaire (ex-émérite)
- KLOSSEK Jean-Michel, Oto-Rhino-Laryngologie
- LAPIERRE Françoise, neurochirurgie (ex-émérite)
- LARSEN Christian-Jacques, biochimie et biologie moléculaire
- LEVILLAIN Pierre, anatomie et cytologie pathologiques
- MAIN de BOISSIERE Alain, pédiatrie
- MARCELLI Daniel, pédopsychiatrie (ex-émérite)
- MARILLAUD Albert, physiologie
- MAUCO Gérard, biochimie et biologie moléculaire (ex-émérite)
- MENU Paul, chirurgie thoracique et cardio-vasculaire (ex-émérite)
- MORICHAU-BEAUCHANT Michel, hépato-gastro-entérologie
- MORIN Michel, radiologie, imagerie médicale
- PAQUEREAU Joël, physiologie
- POINTREAU Philippe, biochimie
- POURRAT Olivier, médecine interne (ex-émérite)
- REISS Daniel, biochimie
- RIDEAU Yves, anatomie
- RODIER Marie-Hélène, parasitologie et mycologie
- SULTAN Yvette, hématologie et transfusion
- TALLINEAU Claude, biochimie et biologie moléculaire
- TANZER Joseph, hématologie et transfusion (ex-émérite)
- TOURANI Jean-Marc, cancérologie
- VANDERMARQ Guy, radiologie et imagerie médicale

REMERCIEMENTS

A Monsieur le Professeur Nicolas Leveziel

Vous me faites le très grand honneur de juger cette thèse. Je vous suis reconnaissant de m'avoir proposé ce travail. Je vous remercie de m'avoir fait profiter durant tout mon internat de votre enseignement universitaire et vos multiples compétences.

Veuillez recevoir l'expression de ma profonde reconnaissance et de tout mon respect.

A Monsieur le Professeur Pierre Ingrand

Je vous remercie de m'avoir fait l'honneur d'accepter de présider et de juger cette thèse. Merci à vous et à votre équipe pour ce travail remarquable et je pense notamment à Simon Marillet.

Veuillez recevoir l'expression de ma sincère reconnaissance et de tout mon respect.

A Monsieur le Professeur Xavier Dufour

Je vous remercie de m'avoir fait l'honneur d'accepter de juger ce travail.

J'ai effectué mon premier semestre d'internat au sein de votre service où vous avez fait preuve d'une grande disponibilité et vos conseils ont été précieux.

Veuillez recevoir l'assurance de ma sincère reconnaissance et de tout mon respect.

A Madame le Docteur Roxane Flausse,

Je te remercie de m'avoir fait l'honneur d'accepter de juger cette thèse.

Je pense qu'un paragraphe ne suffit pas pour te remercier. Tu m'as donné l'envie de faire de l'orbito palpébrale. Tu as toujours fait preuve d'une grande patience à mon égard et surtout d'une grande bienveillance. Tu fais preuve de qualités humaines fondamentales dont j'ai pu m'inspirer. J'ai pu profiter durant toutes ces années de tes talents chirurgicaux et de ton enseignement.

Sois assurée de toute ma reconnaissance et de mon affection.

A Anaïs, ma femme, qui a toujours été à mes côtés et m'a toujours soutenu. Merci de faire de moi l'homme le plus heureux du monde.

A Lou, ma petite princesse, ma lune, te voir grandir chaque jour et voir ton sourire sont les plus belles choses qui me soient jamais arrivées.

A ma maman, qui a toujours veillé sur moi et qui après avoir été la meilleure maman du monde est désormais la meilleure mamie du monde. A mon papa, merci de m'avoir toujours poussé et fait comprendre qu'avec volonté et travail je pouvais réussir tout ce que j'entreprenais.

A mon frère, Jérémy, pas seulement un modèle pour ton courage et ton travail mais pour la personne que tu es. A Aurélie, une belle sœur formidable et à ma petite Romy qui saura montrer à Lou les plus belles choses de la vie.

A mes grands parents, à ma tante Domie.

A mamie Jeannine

A mon oncle et ma tante Jean Francois et Annette. A mes cousins et cousines Paul, Emilie et Marie et leurs familles.

A ma belle famille, Philippe, Nicole, Lucile et Antoine. Merci de m'avoir accueilli dans votre magnifique famille. Evidemment je pense à Hortense qui n'est pas encore là mais qui sera une formidable cousine vu comment ses parents sont géniaux.

A mes amis de toujours, Côme, Romain, Florent et leurs femmes Clémence, Juliette et Valentine. A leurs magnifiques enfants, Romane ma petite filleule d'amour et la sublime Simone.

A mes fidèles compagnons de médecine, Liab, Luc, Adrien, Thibaut et Martin.

A toute l'équipe de médecine de Limoges, Desvilles, Chedaille, Pierro, Aris, Mich, Ricou, JB, Cailloce, Pistache et j'oublie pas les filles dont il a fallu beaucoup de patience pour nous supporter toutes ces années, Chacha, Bett, Cleber, Clémence, Alienor, Léa, Suzanne et j'en oublie sûrement...

A tout le service d'ophtalmologie de Poitiers,

A Clément, mon petit chat, heureux d'être devenu ton ami et aussi plus récemment ton voisin.

A Marion, ma collègue d'orbito palpébral, merci de ta disponibilité au travail mais aussi en dehors.

A Alice, merci pour ta bonne humeur et ta douceur.

A Maxime, ancien co interne et désormais chef de clinique au top. Le surnom de petit prince de l'ophtalmologie te va vraiment bien. A ta patience qu'il te faudra pour me supporter l'an prochain.

A Martial, merci d'être toujours là pour le service et de partager avec les internes ton expérience au travers des milliers d'avis que tu nous donnes.

A Olivier

A Eliette et Camille, la joyeuse équipe de Montmorillon.

A tous mes co internes, Hector dont la principale qualité est de supporter le PSG, Alexandre « El Duche » avec qui je voudrais toujours partager un bon chabrot en fin de repas, Guillaume, premier complice et soutien dans ma connerie, merci de me supporter. A tous les autres, JB, Camille, Gaelle, Vincent, Antoine, Nathan, Geoffrey, Mathieu, Omar.

A Quentin, pour tout ce que tu m'as appris durant nos années de co internes et durant ton clinicat. Beaucoup de bons moments en consultation. Bon vent à La Réunion

A JG et JE, gardez votre bonne humeur

A Mélissa, sois heureuse dans ta nouvelle vie à Tahiti

A, Isabelle, Dorothée, Loubna, Marie France, Eloïse, Laure, Patricia

A toute l'équipe du bloc opératoire

A toute l'équipe de La Rochelle,

A Mr Gobert, merci de m'avoir appris la définition du dépassement de soi. A Emilie, pour sa gentillesse. A Samy, qui n'oubliera jamais la règle des 3 R. A Alex Palacin, pour sa bonne humeur et ses talents culinaires.

SOMMAIRE

ABREVIATIONS	8
INTRODUCTION	10
MATERIALS AND METHODS.....	11
RESULTS	14
DISCUSSION	21
CONCLUSION.....	25
REFERENCES	26
ABSTRACT.....	31
SERMENT	32

ABBREVIATIONS

BLINK : Bifocal Lenses In Nearsighted Kids

CIs : confidence intervals

D : diopters

IRB : Institutional review board

SE : spherical equivalent

Progression of myopia in children and teenagers: a nationwide longitudinal study

Dorian Tricard^{1*}, Simon Marillet^{1,2*}, Pierre Ingrand^{2,3}, Mark Bullimore⁴, Rupert Bourne⁵, Nicolas Leveziel^{1,3,5,6,7}

Corresponding author: Nicolas Leveziel; email address : nicolas.leveziel@yahoo.fr

Phone number: +(33) 663 006 122. * These authors share the same authorship.

¹ CHU Poitiers, Department of ophthalmology, Poitiers, France

² Public Health department, University of Poitiers, Poitiers, France

³ CIC 1402, Poitiers, France

⁴University of Houston College of Optometry, Houston, Texas, USA

⁵ Vision and Eye research Institute, Cambridge, UK

⁶ INSERM 1084, Poitiers, France

⁷ University of Poitiers, Poitiers, France

British Journal of Ophthalmology 2021

doi:10.1136/bjophthalmol-2020-318256

INTRODUCTION

A “myopia boom” has been observed in many countries, mainly in South-East Asia, but also worldwide, making myopia a major public health issue.[1] Myopia is defined by a refractive error of -0.50 diopter (D) or less, and high myopia by refractive errors of -5 D or less, and in 2020 they affect 2.6 billion and 300 million people respectively worldwide (<https://www.who.int/blindness/causes/MyopiaReportforWeb.pdf>). Accelerated evolution of lifestyles over recent decades, with more time dedicated to close-range work and mid-distance activities, combined with marked reduction of outdoor activities and more extensive educational coverage, likely explain this epidemic to a far greater extent than genetic modifications, which usually require much more time. [2–7]

Myopia frequently appears in childhood, with a peak incidence occurring between eight and ten years of age.[8,9] There is major disparity in the prevalence of myopia in children according to ethnic origin.[10] The progression of myopia has been analyzed in various studies,[8,11–13] and a younger age of myopia onset or longer duration of myopia progression are strong predictors of high myopia.[8,14,15]

Epidemiologic data on European myopic children are scarce, particularly with respect to myopia progression, with most studies focusing on refractive error in adults. The aim of this study was to prospectively study myopia progression among children and adolescents in France.

MATERIALS AND METHODS

Dataset description and selection

The original dataset consisted of anonymized electronic data files collected from 696 French opticians' stores located in all French metropolitan departments between 2013 and 2019. Information came from the optical prescriptions provided by ophthalmologists. Relevant variables were year of birth, sex, prescription date, purchase date, type of prescription (glasses, contact lenses), type of vision correction (near vision, distance vision, progressive glasses, others), sphere and cylinder characteristics for both eyes. The spherical equivalent of the right eye only was used to quantify myopia. Myopia was defined by a spherical equivalent (SE) less than or equal to -0.50 D.[16]

Individuals with at least two prescriptions for myopia correction separated by at least six months were eligible, the first prescription for myopia correction in opticians' stores participating in the study being considered as the baseline. One estimate of progression rate was calculated per individual, using the last prescription. Age of myopia incidence was not known, as baseline refractive error varied considerably.

Inclusion criteria were myopia age between 4 and 17 years at the date of first prescription. Children aged 0 to 3 years were excluded because of their relatively small number and because myopia etiology is considered different for preschoolers.[17] Preprocessing and further exclusion steps are summarized in Figure 1. The most frequent reasons for exclusion were age and refractive error.




Figure 1. Flow diagram describing data selection

Myopia progression was defined as the difference in SE between baseline and subsequent prescriptions. Negative values represent myopia progression. Time intervals between visits were categorized into six-month intervals. In cases of multiple prescriptions within an interval, the visit with the most myopic prescription was selected, usually the last one. Progressors were defined as individuals with a mean rate of progression of myopia exceeding -0.50 D/year in the period between baseline and a second prescription between 11 and 24 months after baseline. Individuals without prescription in this period were excluded from the corresponding analyses.

When comparing the progression of progressors and non-progressors, the second prescription was used as the new baseline.

High myopia was defined as an $SE \leq -6D$. For survival analysis, only individuals who did not have high myopia were selected. The incidence date of high myopia was set as the earliest prescription for high myopia. When high myopia did not occur, the latest prescription date was used (censored observation). To avoid bias due to low number of at-risk individuals, prescriptions that occurred more than 5.5 years after baseline were treated as censored at 5.5 years.

The study adhered to the tenets of the Declaration of Helsinki and has been approved by the Ethics Committee of the French Society of Ophthalmology (IRB 00008855).

Modeling

We modeled progression with an ANOVA. Covariates included age, SE at baseline and gender, and the main variable was progression between 11 and 24 months after baseline.

The p-values for proportions of progressors were computed using logistic regression to model “progressor status” (positive if the progression rate is < -0.50 D/year). Covariates were age group, SE at baseline and gender.

Survival analysis was performed with a multivariate Cox model including the following covariates age, SE at baseline and gender.

Patient and Public Involvement statement

Patients and the public were not involved in any way during this research.

RESULTS

Dataset description

The dataset included 136,333 myopic children and teenagers (mean age: 11.3 ± 3.8 ; 55.0% were female, 130,678 had an SE > -6 D). Median follow-up was 2.7 years. Follow-up duration was ≥ 2 years, ≥ 3 years, ≥ 4 years, and ≥ 5 years for 90,706 (66.5%), 61,062 (44.8%), 36,989 (27.1%), and 17,995 (13.2%) participants respectively. Progressor status could be determined for 88,604 of them (second prescription 11 to 24 month after baseline) and 50,516 of the latter had a visit following the second prescription to estimate later progression. Demographic characteristics and refractive data are detailed in Table 1.

	N	Age (Mean \pm SD)	Gender (Female, %)	Sphere (Mean \pm SD)
Age groups				
All	136,333	11.3 ± 3.8	55.0	-2.10 ± 1.80
4 - 6	19,179	5.0 ± 0.8	51.9	-1.90 ± 1.67
7 - 9	25,830	8.1 ± 0.8	52.5	-1.78 ± 1.57
10 - 12	33,319	11.1 ± 0.8	55.3	-2.03 ± 1.72
13 - 15	36,861	14.0 ± 0.8	56.5	-2.29 ± 1.90
16 - 17	21,144	16.5 ± 0.5	57.6	-2.48 ± 1.99
With progression status	88,604	11.0 ± 3.8	54.8	-2.12 ± 1.80
With progression status and follow-up	50,516	10.4 ± 3.6	53.4	-2.20 ± 1.84
Progressors	13,795	10.2 ± 3.2	55.3	-2.37 ± 1.92
Non-progressors	36,721	10.7 ± 3.7	52.7	-2.14 ± 1.81
Mild or moderate myopia	130,678	11.2 ± 3.8	55.0	-1.85 ± 1.27

Table 1. Sample demographic and refractive characteristics

Progression of myopia

Progression among age groups was significantly different ($p < 0.0001$), with a higher proportion of progressors among children aged 7–9 years (33.1 %) and 10–12 years (29.4%) compared to other groups (at most 22.1 %). Moreover, progression differed significantly in relation to SE ($p < 0.0001$), with a higher proportion of progressors among individuals with SE ≤ -4.00 D (30.0%) than for others (at most 27.5 %). Finally, progression differed significantly between sexes, ($p < 0.0001$) with a higher proportion progression among girls (25.6%) than among boys (24.1 %). These numbers are detailed in Table 2.

	% Progressors (N = 88,604)	% with unknown progressor status (N = 136,333)
All	24.9	35.0
Age groups		
4 to 6	20.6	29.9
7 to 9	33.1	31.2
10 to 12	29.4	32.9
13 to 15	22.1	37.9
16 to 17	14.9	42.5
SE		
-1 to -0.5	19.3	36.2
-2 to -1	25.6	34.6
-3 to -2	27.3	35.0
-4 to -3	27.5	34.1
≤ -4	30.0	34.3
Gender		
F	25.6	35.3
M	24.1	34.7

Table 2. Proportion (%) of progressors by age at baseline, SE at baseline and sex.

Progression of myopia as a function of age at first myopia correction

The rate of myopia progression was essentially linear with time within age groups, the most rapid progression being observed for children aged 7 to 9 and 10 to 12 years at baseline (-0.43 D and -0.42 D) (Figure 2A, Table 3). Progression rate was lower for younger and older age groups, and the association between age and progression rate was nonlinear.

Progression as a function of spherical equivalent on first myopia correction

Children with SE inferior to -1 D myopia at baseline had faster progression (at least -0.33 D in multivariate analysis) than those with milder myopia (-0.23 D) (Figure 2B, Table 3). Rates for the other four categories of myopia were very similar (between -0.38 and -0.40 D).

Regardless of baseline myopia, progression rate was highest for children aged 7 to 9 years. In particular, individuals with $SE \leq -4$ D at 9 years had a mean progression of -1.6 D four to five years later. While the rate of progression was higher for more severe degrees of myopia, the pattern of progression followed a U shape similar between different myopia subgroups (Figure 3).

Myopia progression according to gender

Average progression of myopia was higher among girls (-0.35 D) than among boys (-0.32 D) (Table 3).

	Univariate Progression	Multivariate Progression
Age		
4 - 6	-0.15 [-0.17; -0.14]	-0.18 [-0.19; -0.16]
7 - 9	-0.40 [-0.41; -0.39]	-0.43 [-0.44; -0.42]
10 - 12	-0.41 [-0.42; -0.40]	-0.42 [-0.43; -0.41]
13 - 15	-0.35 [-0.36; -0.34]	-0.36 [-0.37; -0.35]
16 - 17	-0.29 [-0.30; -0.27]	-0.29 [-0.30; -0.28]
SE		
-0.5 to -1	-0.25 [-0.26; -0.24]	-0.23 [-0.24; -0.22]
-2 to -1	-0.35 [-0.36; -0.34]	-0.33 [-0.34; -0.32]
-3 to -2	-0.38 [-0.39; -0.37]	-0.36 [-0.37; -0.35]
-4 to -3	-0.38 [-0.40; -0.37]	-0.37 [-0.38; -0.36]
<= -4	-0.40 [-0.41; -0.39]	-0.38 [-0.39; -0.37]
Sex		
F	-0.35 [-0.35; -0.34]	-0.35 [-0.35; -0.34]
M	-0.32 [-0.33; -0.32]	-0.32 [-0.33; -0.31]

Table 3. Average myopia progression (in diopters) between 11 and 24 months according to age, spherical equivalent at baseline and gender: univariate and multivariate analysis. Type 3 test p-values for the multivariate model: age ($p<0.0001$), SE ($p<0.0001$), gender ($p<0.0001$).




Figure 2. (A) Average progression of myopia (in diopters) as a function of time (in years) stratified by baseline age groups. Bars display 95% CIs. (B) Average progression of myopia (in diopters) as a function of time (in years) stratified by baseline spherical equivalent (SE). Bars display 95% CIs.




Figure 3. Average progression of myopia at 4 to 5 years after baseline; as a function of baseline age stratified by baseline spherical equivalent (SE). Bars display 95% CIs.

Later myopia progression according to initial progression rate

Progressors as defined during the first 11 to 24 months showed faster rates of progression than non-progressors in the follow-up period with a change equal to -1.69 D $[-1.56; -1.81]$ versus -0.87 D $[-0.79; -0.95]$ 5 to 5.5 years after baseline. This was observed in all age groups (Figure 4).




Figure 4. Comparison of average progression of myopia (in diopters) as a function of time (in years) between progressors and non-progressors, stratified by age at baseline. (A) between 4 and 12 years, (B) between 13 and 17 years. ‘Second prescription’ refers to the prescription used to characterise the progression status with respect to baseline (first prescription). Bars display 95% CIs.

Time to develop high myopia

Univariate analysis showed that children with a SE ≤ -4.00 D and > -6.00 D at baseline had 58% risk to develop high myopia at 5.5 years follow-up (Figure 5).

Multivariate analysis (Table 4) showed that younger individuals aged 4–12 years, girls and individuals with higher myopia at baseline were more likely to develop high myopia (Table 4).

	Multivariate hazard ratio [95% CI]
Age	p-value < 0.0001
4 - 6	2.07 [1.85; 2.31]
7 - 9	2.59 [2.34; 2.86]
10 - 12	2.06 [1.88; 2.27]
13 - 15	1.33 [1.21; 1.46]
16 - 17	Reference
SE	p-value < 0.0001
-0.5 to -1	Reference
-2 to -1	4.78 [3.16; 7.22]
-3 to -2	17.81 [11.96; 26.52]
-4 to -3	56.73 [38.34; 83.96]
<= -4	398.35 [270.80; 585.99]
Sex	p-value < 0.0001
M	Reference
F	1.18 [1.12; 1.25]

Table 4. Hazard ratios and 95% CI for the event “develops high myopia” from a multivariate Cox model. Type 3 test p-values are displayed.




Figure 5. Kaplan-Meier failure curves for the event ‘develops highmyopia’ stratified by spherical equivalent at baseline.

DISCUSSION

The objective of our study was to describe the progression of myopia in France using a cohort of individuals aged 4 to 17 years at baseline and followed for up to 6.5 years from 2013 to 2019.

This study showed that factors associated with faster myopia progression were gender, with girls being more prone to progression than boys, higher myopia at baseline, and age between 7 and 12 years. The large sample size results in a number of significant differences that are clinically unremarkable. For example, the faster progression in females amounts to only 0.18 D over six years. The differences among myopia levels less than -1 D are similarly small and not clinically meaningful.

In the current study we observed a small difference of 0.03 D or 9% difference in terms of myopia progression between girls and boys. The literature shows that myopic girls progress slightly faster than myopic boys. Hyman et al. show a difference of 0.16 D over three years ($p < 0.05$), but there was no difference in axial elongation.[18] Similarly, Donovan et al. considered the effect of gender in their meta-analysis on the rates of myopia progression. For an average baseline age of 8.8 years, estimated annual progression was significantly faster ($p < 0.01$) for females (-0.80 D) than for males (-0.71 D).[12] This difference has been also observed in Indian and Chinese studies [19,20] along with other longitudinal studies of North American children. [21]

Despite these convergent results, it is difficult to explain this difference. Slightly more near work activity or less outdoor time among girls could be supposed, but it still remains speculations.

Age is the most important factor determining the mean progression rate and the proportion of fast progressors, but age is not a monotonic factor, with 7 to 9 year old myopes progressing faster and both younger and older children progressing more slowly. The slower progression in younger children, with very young onset of myopia could reflect a different etiology. They have not been studied as frequently as school-age myopes and future research may cast light on this hypothesis,

Few prospective studies have shown the relationship between age at myopia onset and myopia severity.[8,15,22] Most of them have focused on a particular age range, from 7 to 9 years [8,22] or from 9 to 12.[15] In the current study, given the large sample size, we were able to evaluate the progression of myopia in different age groups, from 4 to 17 years old, and showed that myopia progressed more rapidly in children aged 7–9 years old and 10–12 years

old, with mean myopia progression of -0.40 D and -0.41 D over 11 to 24 months, respectively. These progression rates are smaller than those reported in different clinical trials conducted in Taiwan, Singapore, China and Hong Kong[23–28] with reported values varying from -0.63 to -2.00 D/year. Ethnicity is clearly an important factor in rate of progression with children of East Asian descent progressing faster than those of European ancestry.[12] This difference could be partially explained by different exposure to environmental and genetic risk factors and by the fact that children included in interventional clinical trials may be more prone to faster progression than those in an observational study. However, the progression reported in our study is relatively close to the mean rate of progression reported in the control arm of children aged 6 to 15 years of the Houston Myopia Control Study (-0.34 D/year),[29] and of myopic children aged 5 to 15 years in the North India Myopia Study (-0.27 D/year).[30] The recently completed Bifocal Lenses In Nearsighted Kids (BLINK) Study reported a three-year progression of -1.05 D in the control group wearing single vision soft lenses (-0.35 D/year).[31] An earlier three-year clinical trial reported a three-year progression of -1.10 D in the control group wearing spectacles (-0.37 D/year).[32] The majority of children in both studies were of European descent and the mean age at baseline was around 10 years.

We also analyzed the percentage of children progressing by at least 0.50 D/year over the first 11 to 24 months, since this is a proposed criterion for the implementation of preventive strategies aimed at reducing myopia progression.[33] In this context, higher proportions of progressors were observed within the 7–9 and 10–12 years old age groups, accounting for 33.1% and 29.4% respectively, compared with 24.9% of the whole cohort (Table 2). Furthermore, the initial progressor profile defined within the 11 to 24 month period following the baseline correction was predictive to higher progression of myopia during the 5.5 years of follow-up for almost all age groups, except for the 16–17 years (Figure 6). This could be explained by the fact that the mean age at myopia stabilization is usually close to this latter age range.[11] We also observed that every diopter at baseline matters a lot in terms of risk to develop high myopia during the follow-up. Indeed, between myopia ranges -3 to -4 and -4 to -6 D (– being excluded), the risk to develop high myopia increased from 17% to 58% (Figure 7). These observations pleads for precise screening and follow-up of myopic children at the era of preventive approaches against myopia progression.

The increased prevalence of myopia in industrialized countries could be largely due to lifestyle, notably a reduction in outdoor activities combined with an increase of close-range work activities and more intensive and extensive educational coverage.[2–7,34–36] Estimates

state that in children a reduction in the risk of myopia is obtained for each hour a week spent outdoors.[34] Furthermore, early exposure to daylight could have a beneficial impact on the development of myopia. Indeed, a Chinese study showed that children born in winter are more prone to become myopic than children born in other seasons.[37] More accurate estimation of myopia progression and its risk factors may be accompanied by more personalized preventive strategies combining a modification of life style[2–7,35,38] and pharmacological [19–27] or optical approaches[31,39] in view of preventing myopia progression. In fact, it is likely that reduction of myopia progression during childhood could have an impact on myopia severity in adulthood and may thereby influence the incidence of myopia-related complications, i.e. glaucoma, cataract, retinal detachment, myopic maculopathy and myopic neovascularization.[40]

Strengths and limitations of this study

This is the first prospective study on myopia including a large sample of over 130,000 children and teenagers. The strength of this study is its design, which provided original data on myopia progression according to age, gender and degree of myopia in a very large, young population over a 6.5-year period. We also acknowledge several weaknesses in this study. First, information on cycloplegia prior to refractive error measurement was not included, even though, according to national recommendations, cycloplegia is usually used in children. This may have resulted in some of the children in the lowest myopia category being misclassified, perhaps accounting for the slower progression rate among these subjects. In longitudinal clinical studies and trials, auto-refraction is preferred. Likewise, axial length was not measured in this study.

Second, children with more rapid and longer myopia progression could be over-represented, given that they would require more frequent changes of optical correction than those with more stable vision. This may explain a paradox in the data: while it is clear that older children progress more slowly (Figure 2), the different age groups do not appear to slow over time. This may be due to more stable children having shorter follow-up and only those who continue to progress attending examination later in the study. Furthermore, the fact that progression rates remain linear within each of the age groups can reflect the fact that prescription of optical correction prevents accelerated progression during the 7–9 year period. Progression in children wearing a myopic correction may be faster compared to those uncorrected, although deliberate undercorrection may accelerate progression.[41] Thus, the inclusion of only children receiving prescriptions in the current study may have influenced

progression rates. Furthermore, because it is likely that a new prescription was done in case of modification of refractive error of ± 0.50 D and no lesser, smaller refractive changes were possibly not reported, despite smaller progression.

CONCLUSION

This is the first French prospective study on myopia in children with a large sample size, providing estimations of myopia progression according to age, gender and initial degree of myopia at first correction.

REFERENCES

- 1 Holden BA, Fricke TR, Wilson DA, *et al.* Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. *Ophthalmology* 2016;**123**:1036–42. doi:10.1016/j.ophtha.2016.01.006
- 2 Rose KA, Morgan IG, Ip J, *et al.* Outdoor Activity Reduces the Prevalence of Myopia in Children. *Ophthalmology* 2008;**115**:1279–85. doi:10.1016/j.ophtha.2007.12.019
- 3 He M, Xiang F, Zeng Y, *et al.* Effect of Time Spent Outdoors at School on the Development of Myopia Among Children in China: A Randomized Clinical Trial. *JAMA* 2015;**314**:1142–8. doi:10.1001/jama.2015.10803
- 4 Ip JM, Saw S-M, Rose KA, *et al.* Role of Near Work in Myopia: Findings in a Sample of Australian School Children. *Invest Ophthalmol Vis Sci* 2008;**49**:2903. doi:10.1167/iovs.07-0804
- 5 Jin J-X, Hua W-J, Jiang X, *et al.* Effect of outdoor activity on myopia onset and progression in school-aged children in northeast china: the sujiatun eye care study. *BMC Ophthalmol* 2015;**15**:73. doi:10.1186/s12886-015-0052-9
- 6 Dirani M, Tong L, Gazzard G, *et al.* Outdoor activity and myopia in Singapore teenage children. *British Journal of Ophthalmology* 2009;**93**:997–1000. doi:10.1136/bjo.2008.150979
- 7 Nickels S, Hopf S, Pfeiffer N, *et al.* Myopia is associated with education: Results from NHANES 1999-2008. *PLoS ONE* 2019;**14**:e0211196. doi:10.1371/journal.pone.0211196
- 8 Chua SYL, Sabanayagam C, Cheung Y-B, *et al.* Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. *Ophthalmic Physiol Opt* 2016;**36**:388–94. doi:10.1111/opo.12305
- 9 Kleinstei RN. New Cases of Myopia in Children. *Arch Ophthalmol* 2012;**130**:1274. doi:10.1001/archophthalmol.2012.1449
- 10 French AN, Morgan IG, Burlutsky G, *et al.* Prevalence and 5- to 6-year incidence and progression of myopia and hyperopia in Australian schoolchildren. *Ophthalmology* 2013;**120**:1482–91. doi:10.1016/j.ophtha.2012.12.018

- 11 Hyman L, Gwiazda, Marsh-Tootle, *et al.* Myopia Stabilization and Associated Factors Among Participants in the Correction of Myopia Evaluation Trial (COMET). *Invest Ophthalmol Vis Sci* 2013;**54**:7871. doi:10.1167/iov.13-12403
- 12 Donovan L, Sankaridurg P, Ho A, *et al.* Myopia Progression Rates in Urban Children Wearing Single-Vision Spectacles: *Optometry and Vision Science* 2012;**89**:27–32. doi:10.1097/OPX.0b013e3182357f79
- 13 Kurtz D, Hyman L, Gwiazda JE, *et al.* Role of Parental Myopia in the Progression of Myopia and Its Interaction with Treatment in COMET Children. *Invest Ophthalmol Vis Sci* 2007;**48**:562. doi:10.1167/iov.06-0408
- 14 Williams KM, Hysi PG, Nag A, *et al.* Age of myopia onset in a British population-based twin cohort. *Ophthalmic Physiol Opt* 2013;**33**:339–45. doi:10.1111/opo.12042
- 15 Jensen H. Myopia in teenagers: An eight-year follow-up study on myopia progression and risk factors. *Acta Ophthalmologica Scandinavica* 1995;**73**:389–93. doi:10.1111/j.1600-0420.1995.tb00294.x
- 16 Flitcroft DI, He M, Jonas JB, *et al.* IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. *Invest Ophthalmol Vis Sci* 2019;**60**:M20–30. doi:10.1167/iov.18-25957
- 17 Logan NS, Gilmartin B, Marr JE, *et al.* Community-based study of the association of high myopia in children with ocular and systemic disease. *Optom Vis Sci* 2004;**81**:11–3. doi:10.1097/00006324-200401000-00004
- 18 Hyman L, Gwiazda J, Hussein M, *et al.* Relationship of age, sex, and ethnicity with myopia progression and axial elongation in the correction of myopia evaluation trial. *Arch Ophthalmol* 2005;**123**:977–87. doi: 10.1001/archoph.123.7.977
- 19 Saxena R, Vashist P, Tandon R, *et al.* Incidence and progression of myopia and associated factors in urban school children in Delhi: The North India Myopia Study (NIM Study). *PLoS ONE* 2017;**12**:e0189774. doi:10.1371/journal.pone.0189774

- 20 Zhou W-J, Zhang Y-Y, Li H, *et al.* Five-Year Progression of Refractive Errors and Incidence of Myopia in School-Aged Children in Western China. *Journal of Epidemiology* 2016;**26**:386–95. doi:10.2188/jea.JE2014025831.
- 21 COMET Group. Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET). *Invest Ophthalmol Vis Sci* 2013;**54**:7871–84. doi:10.1167/iovs.13-12403
- 22 Saw S-M, Tong L, Chua W-H, *et al.* Incidence and Progression of Myopia in Singaporean School Children. *Invest Ophthalmol Vis Sci* 2005;**46**:51. doi:10.1167/iovs.04-056523.
- 23 Yen MY, Liu JH, Kao SC, *et al.* Comparison of the effect of atropine and cyclopentolate on myopia. *Ann Ophthalmol* 1989;**21**:180–2, 187.
- 24 Chua W-H, Balakrishnan V, Chan Y-H, *et al.* Atropine for the Treatment of Childhood Myopia. *Ophthalmology* 2006;**113**:2285–91. doi:10.1016/j.ophtha.2006.05.062
- 25 Yi S, Huang Y, Yu S-Z, *et al.* Therapeutic effect of atropine 1% in children with low myopia. *J AAPOS* 2015;**19**:426–9. doi:10.1016/j.jaapos.2015.04.006
- 26 Wang Y, Bian H-L, Wang Q. Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial. *Medicine* 2017;**96**:e7371. doi:10.1097/MD.00000000000007371
- 27 Yam JC, Jiang Y, Tang SM, *et al.* Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. *Ophthalmology* 2019;**126**:113–24. doi:10.1016/j.ophtha.2018.05.029
- 28 Fan DSP, Lam DSC, Lam RF, *et al.* Prevalence, Incidence, and Progression of Myopia of School Children in Hong Kong. *Invest Ophthalmol Vis Sci* 2004;**45**:1071. doi:10.1167/iovs.03-1151
- 29 Grosvenor T, Perrigin DM, Perrigin J, *et al.* Houston Myopia Control Study: a randomized clinical trial. Part II. Final report by the patient care team. *Am J Optom Physiol Opt* 1987;**64**:482–98.

- 30 Saxena R, Vashist P, Tandon R, *et al.* Incidence and progression of myopia and associated factors in urban school children in Delhi: The North India Myopia Study (NIM Study). *PLoS ONE* 2017;**12**:e0189774. doi:10.1371/journal.pone.018977431
- 31 Walline JJ, Walker MK, Mutti DO, *et al.* Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The BLINK Randomized Clinical Trial. *JAMA* 2020;**324**:571–80. doi:10.1001/jama.2020.10834
- 32 Walline JJ, Jones LA, Sinnott L, *et al.* A randomized trial of the effect of soft contact lenses on myopia progression in children. *Invest Ophthalmol Vis Sci* 2008;**49**:4702–6. doi:10.1167/iovs.08-2067
- 33 Walline JJ, Lindsley K, Vedula SS, *et al.* Interventions to slow progression of myopia in children. *Cochrane Database of Systematic Reviews* Published Online First: 7 December 2011. doi:10.1002/14651858.CD004916.pub331
- 34 Rose KA, Morgan IG, Smith W, *et al.* Myopia, lifestyle, and schooling in students of Chinese ethnicity in Singapore and Sydney. *Arch Ophthalmol* 2008;**126**:527–30. doi:10.1001/archopht.126.4.527
- 35 French AN, Ashby RS, Morgan IG, *et al.* Time outdoors and the prevention of myopia. *Experimental Eye Research* 2013;**114**:58–68. doi:10.1016/j.exer.2013.04.018
- 36 Wang J, Li Y, Musch DC, *et al.* Progression of Myopia in School-Aged Children After COVID-19 Home Confinement. *JAMA Ophthalmol* 2021:e206239. doi:10.1001/jamaophthalmol.2020.6239.
- 37 Ma Q, Xu W, Zhou X, *et al.* The Relationship of Season of Birth with Refractive Error in Very Young Children in Eastern China. *PLoS ONE* 2014;**9**:e100472. doi:10.1371/journal.pone.0100472
- 38 Wu P-C, Tsai C-L, Wu H-L, *et al.* Outdoor activity during class recess reduces myopia onset and progression in school children. *Ophthalmology* 2013;**120**:1080–5. doi:10.1016/j.ophtha.2012.11.009

- 39 Chamberlain P, Peixoto-de-Matos SC, Logan NS, *et al.* A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. *Optom Vis Sci* 2019;**96**:556–67. doi:10.1097/OPX.0000000000001410
- 40 Qiu M, Wang SY, Singh K, *et al.* Association between Myopia and Glaucoma in the United States Population. *Invest Ophthalmol Vis Sci* 2013;**54**:830. doi:10.1167/iovs.12-11158
- 41 Logan NS, Wolffsohn JS. Role of un-correction, under-correction and over-correction of myopia as a strategy for slowing myopic progression. *Clin Exp Optom* 2020;**103**:133–7. doi:10.1111/cxo.12978

ABSTRACT

BACKGROUND

Data on myopia prevalence and progression in European children are sparse. The aim of this work was to evaluate the progression of myopia in children and teenagers in a large prospective study.

METHODS

A prospective study involving a nationwide cohort. Myopia was defined as a spherical equivalent of less than or equal to -0.50 diopters. Data on refractive error, gender and age were collected during seven consecutive years. Data were collected in 696 optical centers in France between 2013 and 2019, including 136,333 children (4–17 years old) in the analysis. Progression of myopia was assessed between the first visit and the last visit over up to 6.5 years.

RESULTS

Mean age was 11.3 ± 3.8 years (55.0% of female). The proportion of children progressing more than -0.50 D per year was higher in age groups 7–9 years and 10–12 years and in children with SE ≤ -4.00 D at first visit, representing 33.1 %, 29.4 % and 30.0% of these groups, respectively. In multivariate analysis, progression during the first 11 to 24 months was higher in the 7 to 9 and 10 to 12 age groups (-0.43 D and -0.42 D respectively), for higher spherical equivalent at baseline (at least -0.33 D for SE ≤ -1 D) and for girls (-0.35 D).

CONCLUSION

This is the first French epidemiological study to investigate myopia progression in a large cohort of children. Sex, age groups and myopia severity are associated with differing rates of progression.

Key words: myopia; myopia progression; pediatric cohort; pathologic myopia; risk factors

SERMENT



En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine. Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail. Admis dans l'intérieur des maisons mes yeux ne verront pas ce qui s'y passe ; ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs ni à favoriser le crime. Respectueux et reconnaissant envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les hommes m'accordent leur estime si je suis fidèle à mes promesses ! Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque !



ABSTRACT

BACKGROUND

Data on myopia prevalence and progression in European children are sparse. The aim of this work was to evaluate the progression of myopia in children and teenagers in a large prospective study.

METHODS

A prospective study involving a nationwide cohort. Myopia was defined as a spherical equivalent of less than or equal to -0.50 diopters. Data on refractive error, gender and age were collected during seven consecutive years. Data were collected in 696 optical centers in France between 2013 and 2019, including 136,333 children (4–17 years old) in the analysis. Progression of myopia was assessed between the first visit and the last visit over up to 6.5 years.

RESULTS

Mean age was 11.3 ± 3.8 years (55.0% of female). The proportion of children progressing more than -0.50 D per year was higher in age groups 7–9 years and 10–12 years and in children with $SE \leq -4.00$ D at first visit, representing 33.1 %, 29.4 % and 30.0% of these groups, respectively. In multivariate analysis, progression during the first 11 to 24 months was higher in the 7 to 9 and 10 to 12 age groups (-0.43 D and -0.42 D respectively), for higher spherical equivalent at baseline (at least -0.33 D for $SE \leq -1$ D) and for girls (-0.35 D).

CONCLUSION

This is the first French epidemiological study to investigate myopia progression in a large cohort of children. Sex, age groups and myopia severity are associated with differing rates of progression.

Key words: myopia; myopia progression; pediatric cohort; pathologic myopia; risk factors